FDAnews Drug Daily Bulletin

Noting that roughly a third of new chemical and biological entities in clinical development are anti-cancer treatments, the European Medicines Agency (EMA) may update its guideline on trials for anti-cancer drugs. The revision would harmonize the main guideline, which was last revised in 2006, with more recent appendices related to progression-free survival, blood-related malignancies and pediatric studies, according to a recently released consultation paper.
Clinical Trials Advisor